Glass articles with low-friction coatings
A coated glass pharmaceutical package may include a body formed from borosilicate glass that meets the Type 1 criteria according to USP <660>. The body may have an interior surface and an exterior surface. A low-friction coating having a thickness of less than 100 microns may be positioned on at least a portion of the exterior surface. The portion of the exterior surface with the low-friction coating may have a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package formed from the same glass composition and the coefficient of friction may not increase by more than 30% after undergoing a depyrogenation cycle at a temperature of from 250° C. to 400° C. for a time period of from 30 seconds to 72 hours.
1. A coated glass pharmaceutical package comprising:
a body formed from a borosilicate glass that meets the Type 1 criteria according to USP <660>, the body having an interior surface and an exterior surface and a wall extending therebetween; and
a low-friction coating having a thickness of less than 100 microns positioned on at least a portion of the exterior surface, wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating has a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package formed from the same glass composition and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation cycle at a temperature of from 250° C. to 400° C. for a time period of from 30 seconds to 72 hours;
wherein the low-friction coating comprises:
a polymer selected from the group consisting of polyimides, fluoropolymers, silsesquioxane-based polymers, and silicone resins; and
a coupling agent disposed between the polymer and the exterior surface of the glass body.
2. The coated glass pharmaceutical package as recited in claim 1 , wherein the coefficient of friction of the coated glass pharmaceutical package is ≦0.6 before undergoing the depyrogenation cycle.
3. The coated glass pharmaceutical package of claim 1 , wherein a light transmission through the coated glass pharmaceutical package is greater than or equal to about 55% of a light transmission through an uncoated glass pharmaceutical package for each wavelength from about 400 nm to about 700 nm.
4. The coated glass pharmaceutical package of claim 3 , wherein the polymer is a polyimide.
5. The coated glass pharmaceutical package of claim 1 , wherein the coupling agent is in direct contact with the exterior surface and the polymer is in direct contact with the coupling agent.
6. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polyimide.
7. The coated glass pharmaceutical package of claim 1 , wherein the depyrogenation cycle comprises exposing the coated glass pharmaceutical package to a temperature of 260° C. for 30 minutes.
8. The coated glass pharmaceutical package of claim 1 , wherein the depyrogenation cycle comprises exposing the coated glass pharmaceutical package to a temperature of from 250° C. to 400° C. for a time period of 30 minutes.
9. The coated glass pharmaceutical package of claim 1 , wherein the depyrogenation cycle comprises exposing the coated glass pharmaceutical package to a temperature of 300° C. for 30 minutes.
10. The coated glass pharmaceutical package of claim 1 , wherein the coupling agent comprises an inorganic material.
11. The coated glass pharmaceutical package of claim 1 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.
12. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a fluoropolymer.
13. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a silicone resin.
14. A coated borosilicate glass pharmaceutical package comprising:
a body formed from a borosilicate glass that meets the Type 1 criteria according to USP <660>, the body having an interior surface and an exterior surface and a wall extending therebetween;
and
a low-friction coating bonded to at least a portion of the exterior surface, wherein:
the coated borosilicate glass pharmaceutical package is thermally stable after exposure to a temperature of at least about 260° C. for 30 minutes;
a light transmission through the coated borosilicate glass pharmaceutical package is greater than or equal to about 55% of a light transmission through an uncoated borosilicate glass pharmaceutical package formed from the same glass composition for each wavelength from about 400 nm to about 700 nm after the exposure to the temperature of at least about 260° C. for 30 minutes; and
the low-friction coating comprises:
a polymer selected from the group consisting of polyimides, fluoropolymers, silsesquioxane-based polymers, and silicone resins; and
a coupling agent disposed between the polymer and the exterior surface of the glass body.
15. The coated borosilicate glass pharmaceutical package of claim 14 , wherein the coated borosilicate glass pharmaceutical package is thermally stable after exposure to a temperature of from about 260° C. to about 400° C. for 30 minutes.
16. The coated borosilicate glass pharmaceutical package of claim 14 , the coated borosilicate glass pharmaceutical package is thermally stable after exposure to a temperature of at least about 300° C. for 30 minutes.
17. The coated glass pharmaceutical package of claim 14 , wherein the polymer is a polyimide.
18. The coated glass pharmaceutical package of claim 14 , wherein the polymer is a fluoropolymer.
19. The coated glass pharmaceutical package of claim 14 , wherein the polymer is a silicone resin.
20. The coated glass pharmaceutical package of claim 14 , wherein the coupling agent comprises an inorganic material.
21. The coated glass pharmaceutical package of claim 14 , wherein the coupling agent is in direct contact with the exterior surface and the polymer is in direct contact with the coupling agent.
22. A coated borosilicate glass pharmaceutical package comprising:
a body formed from a borosilicate glass that meets the Type 1 criteria according to USP <660>;
the body having an interior surface and an exterior surface and a wall extending therebetween; and
a low-friction coating bonded to at least a portion of the exterior surface, wherein:
the portion of the exterior surface of the coated borosilicate glass pharmaceutical package with the low-friction coating has a coefficient of friction of less than or equal to 0.7, the coefficient of friction is a maximum coefficient of friction measured relative to a second coated borosilicate glass pharmaceutical package in a vial-on-vial testing jig under a normal load of 30 N, the second coated borosilicate glass pharmaceutical package formed from the same glass composition and comprising the low-friction coating on at least a portion of a second exterior outer surface of the second coated borosilicate glass pharmaceutical package and subjected to the same environmental conditions prior to measurement of the coefficient of friction;
the portion of the exterior surface of the coated borosilicate glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated borosilicate glass pharmaceutical package in the vial-on-vial testing jig under the normal load of 30 N and after exposing the coated borosilicate glass pharmaceutical package and the second coated borosilicate glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes; and
the low-friction coating comprises:
a polymer selected from the group consisting of polyimides, fluoropolymers, silsesquioxane-based polymers, and silicone resins; and
a coupling agent disposed between the polymer and the exterior surface of the glass body.
23. The coated glass pharmaceutical package of claim 22 , wherein the polymer is a polyimide.
24. The coated glass pharmaceutical package of claim 22 , wherein the polymer is a fluoropolymer.
25. The coated glass pharmaceutical package of claim 22 , wherein the polymer is a silicone resin.
26. The coated glass pharmaceutical package of claim 22 , wherein the portion of the exterior surface of the coated borosilicate glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated borosilicate glass pharmaceutical package in the vial-on-vial testing jig under the normal load of 30 N and after exposing the coated borosilicate glass pharmaceutical package and the second coated borosilicate glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.
27. The coated glass pharmaceutical package of claim 22 , wherein the portion of the exterior surface of the coated borosilicate glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated borosilicate glass pharmaceutical package in the vial-on-vial testing jig under the normal load of 30 N and after exposing the coated borosilicate glass pharmaceutical package and the second coated borosilicate glass pharmaceutical package to a temperature of from about 260° C. to about 400° C. for 30 minutes.
28. The coated glass pharmaceutical package of claim 22 , wherein the coupling agent comprises an inorganic material.
29. The coated glass pharmaceutical package of claim 22 , wherein the coupling agent is in direct contact with the exterior surface and the polymer is in direct contact with the coupling agent.